Avanir Captures The Alamo; Acquisition Will Give Avanir FazaClo
This article was originally published in The Pink Sheet Daily
Executive Summary
Acquisition of the schizophrenia therapy FazaClo will complement Avanir’s Neurodex, which is under review at FDA.
You may also be interested in...
Avanir Divests FazaClo To Azur Pharma To Fund Zenvia Studies
Azur Pharma will pay $42 million up front to acquire the schizophrenia medication and commercial infrastructure.
Avanir Divests FazaClo To Azur Pharma To Fund Zenvia Studies
Azur Pharma will pay $42 million up front to acquire the schizophrenia medication and commercial infrastructure.
No Laughing Matter: Avanir Resubmits Neurodex NDA
The firm is requesting priority review for involuntary emotional expression disorder.